Skip to main content

Alymsys Dosage

Generic name: BEVACIZUMAB 100mg in 4mL
Dosage form: injection, solution
Drug class: VEGF/VEGFR inhibitors

Medically reviewed by Drugs.com. Last updated on Apr 27, 2022.

Important Administration Information

Withhold for at least 28 days prior to elective surgery. Do not administer Alymsys until at least 28 days following major surgery and until adequate wound healing.

Metastatic Colorectal Cancer

The recommended dosage when Alymsys is administered in combination with intravenous fluorouracil-based chemotherapy is:

  • 5 mg/kg intravenously every 2 weeks in combination with bolus-IFL.
  • 10 mg/kg intravenously every 2 weeks in combination with FOLFOX4.
  • 5 mg/kg intravenously every 2 weeks or 7.5 mg/kg intravenously every 3 weeks in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy in patients who have progressed on a first-line bevacizumab product-containing regimen.

First-Line Non-Squamous Non-Small Cell Lung Cancer

The recommended dosage is 15 mg/kg intravenously every 3 weeks in combination with carboplatin and paclitaxel.

Recurrent Glioblastoma

The recommended dosage is 10 mg/kg intravenously every 2 weeks.

Metastatic Renal Cell Carcinoma

The recommended dosage is 10 mg/kg intravenously every 2 weeks in combination with interferon alfa.

Persistent, Recurrent, or Metastatic Cervical Cancer

The recommended dosage is 15 mg/kg intravenously every 3 weeks in combination with paclitaxel and cisplatin or in combination with paclitaxel and topotecan.

Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Recurrent Disease

Platinum Resistant

The recommended dosage is 10 mg/kg intravenously every 2 weeks in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan (every week).

The recommended dosage is 15 mg/kg intravenously every 3 weeks in combination with topotecan (every 3 weeks).

Dosage Modifications for Adverse Reactions

Table 1 describes dosage modifications for specific adverse reactions. No dose reductions for Alymsys are recommended.

Table 1: Dosage Modifications for Adverse Reactions

Adverse Reaction

Severity

Dosage Modification

Gastrointestinal Perforations and Fistulae [see Warnings and Precautions (5.1)].

  • Gastrointestinal perforation, any grade
  • Tracheoesophageal fistula, any grade
  • Fistula, Grade 4
  • Fistula formation involving any internal organ

Discontinue Alymsys

Wound Healing Complications [see Warnings and Precautions (5.2)].

  • Any

Withhold Alymsys until adequate wound healing. The safety of resumption of bevacizumab products after resolution of wound healing complications has not been established.

  • Necrotizing fasciitis

Discontinue Alymsys

Hemorrhage [see Warnings and Precautions (5.3)].

  • Grade 3 or 4

Discontinue Alymsys

  • Recent history of hemoptysis of 1/2 teaspoon (2.5 mL) or more

Withhold Alymsys

Thromboembolic Events [see Warnings and Precautions (5.4, 5.5)].

  • Arterial thromboembolism, severe

Discontinue Alymsys

  • Venous thromboembolism, Grade 4

Discontinue Alymsys

Hypertension [see Warnings and Precautions (5.6)].

  • Hypertensive crisis
  • Hypertensive encephalopathy

Discontinue Alymsys

  • Hypertension, severe

Withhold Alymsys if not controlled with medical management; resume once controlled

Posterior Reversible Encephalopathy Syndrome (PRES) [see Warnings and Precautions (5.7)].

  • Any

Discontinue Alymsys

Renal Injury and Proteinuria [see Warnings and Precautions (5.8)].

  • Nephrotic syndrome

Discontinue Alymsys

  • Proteinuria greater than or equal to 2 grams per 24 hours in absence of nephrotic syndrome

Withhold Alymsys until proteinuria less than 2 grams per 24 hours

Infusion-Related Reactions [see Warnings and Precautions (5.9)].

  • Severe

Discontinue Alymsys

  • Clinically significant

Interrupt infusion; resume at a decreased rate of infusion after symptoms resolve

  • Mild, clinically insignificant

Decrease infusion rate

Congestive Heart Failure [see Warnings and Precautions (5.12)].

Any

Discontinue Alymsys

Preparation and Administration

Preparation

  • Use appropriate aseptic technique.
  • Visually inspect vial for particulate matter and discoloration prior to preparation for administration. Discard vial if solution is cloudy, discolored or contains particulate matter.
  • Withdraw necessary amount of Alymsys and dilute in a total volume of 100 mL of 0.9% Sodium Chloride Injection, USP. DO NOT ADMINISTER OR MIX WITH DEXTROSE SOLUTION.
  • Discard any unused portion left in a vial, as the product contains no preservatives.
  • Store diluted Alymsys solution at 2°C to 8°C (36°F to 46°F) for up to 12 hours.
  • No incompatibilities between Alymsys and polyvinylchloride or polyolefin bags have been observed.

Administration

  • Administer as an intravenous infusion.
  • First infusion: Administer infusion over 90 minutes.
  • Subsequent infusions: Administer second infusion over 60 minutes if first infusion is tolerated. Administer all subsequent infusions over 30 minutes if second infusion over 60 minutes is tolerated.

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.